Proactive Investors - Run By Investors For Investors

Cosmos Holdings appoints top portfolio manager to advisory board

Tom Kolefas joins the international pharmaceutical company after managing both mutual fund and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York
board room
The appointment of Kolefas follows the recent addition of Anastasios Tzikas, former CEO of Singular Northern Greece SA, one of Greece’s largest software vendors, to the Cosmos board

Cosmos Holdings Inc (OTCQB:COSM) announced Friday that portfolio manager Tom Kolefas has been tapped to serve on its advisory board.

Kolefas joins the international pharmaceutical company after more than 25 years spent on Wall Street’s buyside where he managed both mutual funds and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York.

READ: Cosmos Holdings acquires Cosmofarm in Greece

Kolefas also boasts considerable industry experience as a chemical engineer and corporate development officer at Engelhard/BASF.

“Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, CEO of Cosmos in a statement. “He has a track record for success in identifying value within the mid-cap space. We look forward to his contribution as we position ourselves for continued growth.”

For his part, Kolefas is eager to come on board at Cosmos and advance its business efforts.

READ: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

“Cosmos has a well-thought out, balanced strategy of organic growth, market share gains, new product introductions and acquisitions to capitalize on the growth in the drug, nutraceutical, vitamin and Europe-only cannabis end-markets in Europe, the U.S. and ultimately, the rest of the world," Kolefas said in a statement.

Cosmos Holdings Inc. is an international pharmaceutical company that specializes in acquiring, developing, and commercializing medicines. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and in the UK.

Cosmos shares closed up 8.3% to hit $3.00 on Thursday.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Article
July 02 2018

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use